Dr RR Baliga's "Got Knowledge Doc" Podkast

📢 New from the SOUL trial!

💊 Oral semaglutide cuts heart attack risk in T2DM 🫀 but shows no benefit for stroke 🧠 or kidney disease 🧫.

A win for adherence, a push for CKM integration! 🔄💡 #Diabetes #Cardiology #NEJM #CKM #GLP1RA @doximity

🏌️‍♂️⛳ Living near golf courses may increase Parkinson's risk!

📊 Case-control study: Risk highest within 1–3 miles

💧 Contaminated groundwater & pesticides likely culprits

🧠 aOR up to 2.98 for 6 miles!

📉 Risk ↓ 13% per mile after 3 miles

🔗 [JAMA 2025] #Neurology #Parkinsons #EnvironmentalHealth #GolfRisk @doximity

🚨 BREAKING: Sotatercept cuts risk by 76% in advanced #PAH!

💉 Targets activin signaling

🫁 Fewer deaths, transplants & hospitalizations

📉 HR 0.24 | Trial stopped early for efficacy

⚠️ Epistaxis, ↑Hgb, telangiectasia noted

🔬 A new era in pulmonary hypertension care! #ZENITHTrial #CardioTwitter 🫀📊 @doximity

🚨New COPD diagnosis alert!🫁

A multidimensional schema using CT 🖼️ + symptoms 😮‍💨 + spirometry 📉 identified high-risk patients missed by GOLD!

📈↑Mortality (HR 1.98)

📉FEV1 decline (–7.7 mL/y)

📊 Reclassified 15% w/o obstruction as COPD!

👉CT matters. #PulmTwitter #COPD #MedTwitter @doximity

🚨 New data! In the KARDIA-2 trial, 🧬 zilebesiran—an RNAi therapeutic—cut SBP by up to 12 mmHg when added to common antihypertensives

💊. One shot, 6 months of BP control!

📉 Promising for poor adherence.

Mild AEs. #Hypertension #Cardiology #RNAi 🌍【JAMA 2025】

🧬 Big win for longevity!

A Nature Aging study shows that combining 💊 trametinib + rapamycin extends lifespan, reduces tumors, and tames inflammation in mice 🐭🔥

Dual geroprotectors = additive benefits without added toxicity 🛡️🕰️

Future of anti-aging? Watch this space 👀

#Aging #Longevity #Geroprotectors #Science 🧪 @doximity

🧠💉 New Lancet study (OPTIMISTmain) shows low-intensity monitoring after thrombolysis in mild strokes may be just as safe as standard care!

💤 Less sleep disruption, 🧑‍⚕️ lighter nursing load, ⚖️ similar outcomes.

Could this change global stroke care? 🌍🏥

#Stroke #Thrombolysis #OPTIMISTmain #Neurology

🚨New A2B Trial in JAMA!

Can 🧪dexmedetomidine or clonidine beat 💉propofol in sedating ICU patients on ventilators?

❌ No faster extubation

⚠️ More bradycardia & agitation

⚖️ Similar mortality

Verdict: No clear winner—tailor sedation to patient needs 🛌👨‍⚕️

#CriticalCare #ICU #SedationTrial

🚨🧠 BREAKING: Tenecteplase before thrombectomy boosts chances of stroke recovery!

💉 Faster reperfusion

📈 Higher functional independence (mRS 0–2 at 90d: 52.9% vs 44.1%)

⚠️ Slight ↑ in sICH, but no major safety red flags

🧪 #BRIDGE_TNK trial rewrites the stroke playbook!

#Stroke #Tenecteplase #NeuroTwitter

Nāgārjuna (c. 150 – c. 250 CE) was an Indian Buddhist monk and philosopher, regarded as the founder of the Madhyamaka (Middle Way) school of Mahāyāna Buddhism.

His most famous work, Mūlamadhyamakakārikā (Root Verses on the Middle Way), presents the concept of śūnyatā (emptiness) and the two truths doctrine, emphasizing dependent origination and rejecting inherent existence.

Nāgārjuna's philosophy has profoundly influenced Mahāyāna thought and continues to shape Buddhist studies and practice today.